
News|Articles|December 13, 2012
FDA updates safety review for smoking-cessation drug
The smoking-cessation drug varenicline (Chantix, Pfizer) may increase the risk of cardiovascular adverse events, according to an updated safety review from FDA.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































